The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2022 | Rationale behind combining a VEGF/Ang2-blocking nanobody and immunotherpay in advanced CRC
Susanna Varkey Ulahannan, MD, The University of Oklahoma College of Medicine, Oklahoma City, OK, explains the rationale behind using a bispecific nanobody targeting VEGF/ANG2 in combination with a PD-1 antibody in advanced colorectal cancer (CRC). VEGF and ANG2 have an immunosuppressive effect on the tumor microenvironment (TME). Therefore, anti-PD-1 would target the immunosuppression in addition to targeting angiogenesis. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022.
